Next Science Ltd
ASX:NXS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1.9), the stock would be worth AU$0.2 (40% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.4 | AU$0.15 |
0%
|
| 3-Year Average | 1.9 | AU$0.2 |
+40%
|
| 5-Year Average | 5 | AU$0.53 |
+267%
|
| Industry Average | 1.6 | AU$0.18 |
+22%
|
| Country Average | 4.1 | AU$0.44 |
+201%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
AU$42.4m
|
/ |
Jul 2025
$22.1m
|
= |
|
|
AU$42.4m
|
/ |
Dec 2025
$39.6m
|
= |
|
|
AU$42.4m
|
/ |
Dec 2026
$50.2m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Next Science Ltd
ASX:NXS
|
42.4m AUD | 1.4 | -3.2 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY | 10.3 | 37.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.4B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 3.4 | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 3.3 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.6B USD | 3.1 | 30.8 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 1.1 | -15.8 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 2.2 | 31.1 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 8.3 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 3.8 | 21.9 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | 95.7 | -36.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 4.1 |
| 70th Percentile | 11.8 |
| Max | 1 679 509.2 |
Other Multiples
Next Science Ltd
Glance View
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
